Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 207

1.

Platelets, diabetes and myocardial ischemia/reperfusion injury.

Russo I, Penna C, Musso T, Popara J, Alloatti G, Cavalot F, Pagliaro P.

Cardiovasc Diabetol. 2017 May 31;16(1):71. doi: 10.1186/s12933-017-0550-6. Review.

2.

Metaflammation: tissue-specific alterations of the NLRP3 inflammasome platform.

Mastrocola R, Aragno M, Alloatti G, Collino M, Penna C, Pagliaro P.

Curr Med Chem. 2017 Apr 7. doi: 10.2174/0929867324666170407123522. [Epub ahead of print]

PMID:
28403789
3.

From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview.

Tocchetti CG, Cadeddu C, Di Lisi D, Femminò S, Madonna R, Mele D, Monte I, Novo G, Penna C, Pepe A, Spallarossa P, Varricchi G, Zito C, Pagliaro P, Mercuro G.

Antioxid Redox Signal. 2017 May 15. doi: 10.1089/ars.2016.6930. [Epub ahead of print]

PMID:
28398124
4.

Cardioprotective effects of calcitonin gene-related peptide in isolated rat heart and in H9c2 cells via redox signaling.

Tullio F, Penna C, Cabiale K, Femminò S, Galloni M, Pagliaro P.

Biomed Pharmacother. 2017 Jun;90:194-202. doi: 10.1016/j.biopha.2017.03.043. Epub 2017 Mar 29.

PMID:
28364596
5.

Myocardial ischemia/reperfusion upregulates the transcription of the Neuregulin1 receptor ErbB3, but only postconditioning preserves protein translation: Role in oxidative stress.

Morano M, Angotti C, Tullio F, Gambarotta G, Penna C, Pagliaro P, Geuna S.

Int J Cardiol. 2017 Apr 15;233:73-79. doi: 10.1016/j.ijcard.2017.01.122. Epub 2017 Jan 31.

PMID:
28162790
6.

Pharmacological Inhibition of NLRP3 Inflammasome Attenuates Myocardial Ischemia/Reperfusion Injury by Activation of RISK and Mitochondrial Pathways.

Mastrocola R, Penna C, Tullio F, Femminò S, Nigro D, Chiazza F, Serpe L, Collotta D, Alloatti G, Cocco M, Bertinaria M, Pagliaro P, Aragno M, Collino M.

Oxid Med Cell Longev. 2016;2016:5271251. doi: 10.1155/2016/5271251. Epub 2016 Dec 8.

7.

Nanoprecipitated catestatin released from pharmacologically active microcarriers (PAMs) exerts pro-survival effects on MSC.

Angotti C, Venier-Julienne MC, Penna C, Femminò S, Sindji L, Paniagua C, Montero-Menei CN, Pagliaro P.

Int J Pharm. 2017 May 25;523(2):506-514. doi: 10.1016/j.ijpharm.2016.11.050. Epub 2016 Nov 22.

PMID:
27887883
8.

A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology.

Maurea N, Spallarossa P, Cadeddu C, Madonna R, Mele D, Monte I, Novo G, Pagliaro P, Pepe A, Tocchetti CG, Zito C, Mercuro G.

J Cardiovasc Med (Hagerstown). 2016 May;17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection:e93-e104. Review.

PMID:
27755247
9.

A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology.

Spallarossa P, Maurea N, Cadeddu C, Madonna R, Mele D, Monte I, Novo G, Pagliaro P, Pepe A, Tocchetti CG, Zito C, Mercuro G.

J Cardiovasc Med (Hagerstown). 2016 May;17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection:e84-e92. Review.

PMID:
27755246
10.

Novel insights in pathophysiology of antiblastic drugs-induced cardiotoxicity and cardioprotection.

Deidda M, Madonna R, Mango R, Pagliaro P, Bassareo PP, Cugusi L, Romano S, Penco M, Romeo F, Mercuro G.

J Cardiovasc Med (Hagerstown). 2016 May;17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection:e76-e83. Review.

PMID:
27755245
11.

Preventing antiblastic drug-related cardiomyopathy: old and new therapeutic strategies.

Cadeddu C, Mercurio V, Spallarossa P, Nodari S, Triggiani M, Monte I, Piras R, Madonna R, Pagliaro P, Tocchetti CG, Mercuro G.

J Cardiovasc Med (Hagerstown). 2016 May;17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection:e64-e75. Review.

PMID:
27755244
12.

Role of biomarkers in monitoring antiblastic cardiotoxicity.

Novo G, Cadeddu C, Sucato V, Pagliaro P, Romano S, Tocchetti CG, Zito C, Longobardo L, Nodari S, Penco M.

J Cardiovasc Med (Hagerstown). 2016 May;17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection:e27-e34. Review.

PMID:
27755240
13.

Pathophysiology of anthracycline cardiotoxicity.

Mele D, Tocchetti CG, Pagliaro P, Madonna R, Novo G, Pepe A, Zito C, Maurea N, Spallarossa P.

J Cardiovasc Med (Hagerstown). 2016 May;17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection:e3-e11. Review.

PMID:
27755237
14.

Hypertension, hypertrophy, and reperfusion injury.

Pagliaro P, Penna C.

J Cardiovasc Med (Hagerstown). 2017 Mar;18(3):131-135. doi: 10.2459/JCM.0000000000000435. Review.

PMID:
27606784
15.

A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology.

Maurea N, Spallarossa P, Cadeddu C, Madonna R, Mele D, Monte I, Novo G, Pagliaro P, Pepe A, Tocchetti CG, Zito C, Mercuro G.

J Cardiovasc Med (Hagerstown). 2016 May;17 Suppl 1:S93-S104. doi: 10.2459/JCM.0000000000000383.

16.

A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology.

Spallarossa P, Maurea N, Cadeddu C, Madonna R, Mele D, Monte I, Novo G, Pagliaro P, Pepe A, Tocchetti CG, Zito C, Mercuro G.

J Cardiovasc Med (Hagerstown). 2016 May;17 Suppl 1:S84-92. doi: 10.2459/JCM.0000000000000381.

17.

Novel insights in pathophysiology of antiblastic drugs-induced cardiotoxicity and cardioprotection.

Deidda M, Madonna R, Mango R, Pagliaro P, Bassareo PP, Cugusi L, Romano S, Penco M, Romeo F, Mercuro G.

J Cardiovasc Med (Hagerstown). 2016 May;17 Suppl 1:S76-83. doi: 10.2459/JCM.0000000000000373.

PMID:
27183528
18.

Preventing antiblastic drug-related cardiomyopathy: old and new therapeutic strategies.

Cadeddu C, Mercurio V, Spallarossa P, Nodari S, Triggiani M, Monte I, Piras R, Madonna R, Pagliaro P, Tocchetti CG, Mercuro G.

J Cardiovasc Med (Hagerstown). 2016 May;17 Suppl 1:S64-75. doi: 10.2459/JCM.0000000000000382.

PMID:
27183527
19.

Pathophysiology of anthracycline cardiotoxicity.

Mele D, Tocchetti CG, Pagliaro P, Madonna R, Novo G, Pepe A, Zito C, Maurea N, Spallarossa P.

J Cardiovasc Med (Hagerstown). 2016 May;17 Suppl 1:S3-S11. doi: 10.2459/JCM.0000000000000378.

PMID:
27183523
20.

Role of biomarkers in monitoring antiblastic cardiotoxicity.

Novo G, Cadeddu C, Sucato V, Pagliaro P, Romano S, Tocchetti CG, Zito C, Longobardo L, Nodari S, Penco M.

J Cardiovasc Med (Hagerstown). 2016 May;17 Suppl 1:S27-34. doi: 10.2459/JCM.0000000000000379.

PMID:
27183522

Supplemental Content

Loading ...
Support Center